Remove 2022 Remove Diabetes Remove Labelling
article thumbnail

Ozempic compensating for Wegovy’s supply shortage due to high demand

Pharmaceutical Technology

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022.

Diabetes 111
article thumbnail

Innovative biologic prefilled syringe approved in EU

European Pharmaceutical Review

This authorises a novel CE-labelled needle for intravitreal injection. Vabysmo 6.0mg is indicated for treating neovascular or wet age-related macular degeneration (nAMD), diabetic macular oedema (DME) and macular oedema following retinal vein occlusion (RVO). Wykoff et al. ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData

Express Pharma

Relyvrio/Albrioza was first approved in the US and Canada in September 2022 for the treatment of ALS. In March, Amylyx announced that Relyvrio, a neuroprotective agent, failed to achieve its primary efficacy endpoints in the global Phase III PHOENIX trial for ALS.

Labelling 104
article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

article thumbnail

From biologics to small molecules – the shift in biopharma’s revenue growth

European Pharmaceutical Review

Between 2022 and 2023, companies including Novo Nordisk and Eli Lilly had “year-on-year (YoY) revenue growth of 31.3 billion in 2023 for its obesity and diabetes blockbuster drugs Ozempic (off-label for obesity) and Wegovy respectively, facilitated the growth. percent, 26 percent, and 19.6 percent, respectively”. percent to $33.7

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. This represents a significant 83% increase in sales between 2022–2029, demonstrating a compound annual growth rate (CAGR) of 9%.